Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42Lymphoma 37Lymphoma, Mantle-Cell 35Lymphoma, Non-Hodgkin 32Multiple Myeloma 30Lymphoma, Follicular 30Hodgkin Disease 23Recurrence 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma, B-Cell, Marginal Zone 18Waldenstrom Macroglobulinemia 12Leukemia 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 9Neoplasms, Plasma Cell 7Lymphoma, T-Cell 6Leukemia, Myeloid, Acute 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Leukemia, B-Cell 5Hematologic Neoplasms 5Sezary Syndrome 4Neoplasms 4Mycosis Fungoides 4Immune System Diseases 4Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3

Interventions

fludarabine phosphate 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Cyclophosphamide 7Mycophenolic Acid 6Lenalidomide 6Dexamethasone 6Tacrolimus 5Bortezomib 4Sirolimus 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2Calcium Dobesilate 2Antilymphocyte Serum 2Allopurinol 2talquetamab 1sargramostim 1pomalidomide 1montanide ISA 51 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Plasma Cell × Bendamustine Hydrochloride × Clear all
NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Thomas Jefferson University

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡